Social Anxiety Disorder (SAD) – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2024 To 2034

Social Anxiety Disorder (SAD) Emerging Therapy and TPP Insights

Thelansis’s “Social Anxiety Disorder (SAD) Emerging Therapy, with Unmet Needs and TPP Insights Report – 2024 To 2034″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Social Anxiety Disorder (SAD) Overview

Social anxiety disorder (SAD) is a common mental health condition that causes people to feel intense anxiety in social situations. It can be divided into two subtypes: generalized SAD and non-generalized SAD. Generalized SAD is characterized by fear of most social situations. People with generalized SAD may worry about being judged, humiliated, or embarrassed in front of others. They may avoid social situations altogether, or they may experience extreme anxiety when they are forced to participate in social activities. Non-generalized SAD is characterized by fear of specific social situations, such as speaking, eating, or using the bathroom. People with non-generalized SAD may be able to function in most social situations, but they may experience extreme anxiety in the situations they fear. SAD can have a significant impact on people’s lives. It can interfere with work, school, relationships, and other important areas of life. People with SAD may avoid social situations altogether, leading to loneliness, isolation, and depression.

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by surveys* with physician / key opinion leaders:

• Survey findings are corroborated and enriched by insights from interviews with leading KOLs

*Survey is customized based on client requirements

Deliverables format:

• PowerPoint presentation
• MS Excel

Key business questions answered:

• Detailed emerging competitive landscape
• Pipeline analysis
• Target patients for emerging therapies
• Key companies
• Key mechanism of actions
• Launch date estimates, etc.
• Clinical trial landscape analysis
• Target patient segments
• Trial endpoints
• Trial design
• Recruitment criteria, etc.
• Unmet Needs and Opportunities
• Performance of key current therapies
• Top areas of unmet needs
• Opportunity sizing for key unmet needs
• Target Product Profiles
• Attributes and levels
• Physician likelihood of prescribing
• Expected patient shares
• KOL insights on key emerging therapies
• Level of awareness
• Expected use / line of therapy
• Extent to fulfil key unmet needs
• KOL quotes

Read more: Social Anxiety Disorder (SAD) – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2024 To 2034